

Literatura ACTA MEDICINAE Speciál 2021 Revmatologie

- 2 **Kardiovaskulární riziko u zánětlivých autoimunitních revmatických onemocnění a jeho ovlivnění léčbou**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 2 **Jaké jsou možnosti a na co si dát pozor při očkování pacientů léčených biologickými a cílenými syntetickými léky modifikujícími průběh choroby**
prof. MUDr. Jiří Vencovský, DrSc. Revmatologický ústav, Praha
- 2 **Jak jsme úspěšní v dosahování léčebného cíle u pacientů s revmatoidní artritidou. Analýza dat z národního registru biologické léčby ATTRA**
doc. MUDr. Jakub Závada, Ph.D. Revmatologický ústav, Praha
- 3 **Jak postupovat u nemocných s revmatoidní artritidou po ukončení léčby prvním inhibítorem TNF? Je vhodnější podávat druhý TNF inhibitor, nebo volit léčivo s jiným mechanismem účinku?**
MUDr. Heřman Mann, Ph.D. Revmatologický ústav, Praha
- 3 **Význam sdíleného rozhodování lékař/pacient pro komunikaci v revmatologii**
MUDr. Liliana Šedová | MUDr. Jana Tomasová Studýnková Revmatologický ústav, Praha
- 3 **Nádorová onemocnění u pacientů s revmatoidní artritidou ve vztahu k podávané terapii**
prof. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a VFN, Praha

Kardiovaskulární riziko u zánětlivých autoimunitních revmatických onemocnění a jeho ovlivnění léčbou

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 Skeoch, S. – Bruce, I. N.: Atherosclerosis in rheumatoid arthritis: is it all about inflammation? *Nat Rev Rheumatol*, 2015, 11, s. 390–400.
- 2 Libby, P.: Inflammation in atherosclerosis. *Arterioscler Thromb Biol*, 2012, 32, s. 2045–2051.
- 3 Keerola, A. M. – Kauppi, M. J., et al.: How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear. *Ann Rheum Dis*, 2012, 71, s. 1606–1615.
- 4 Myllykangas, R. – Aho, K. – Kuitanen, H., et al.: Cardiovascular mortality in women with rheumatoid arthritis. *J Rheumatol*, 1995, 22, s. 1065–1067.
- 5 Peters, M., et al.: EULAR evidence-based recommendations for cardiovascular management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. *Ann Rheum Dis*, 2010, 69, s. 325–331.
- 6 Ungprasert, P. – Srivali, N. – Kittanamongkolchai W.: Risk of coronary artery disease in patients with AS? A systematic review and meta-analysis. *Ann Transl Med*, 2015, 3, s. 51.
- 7 Han, C. H. – Robinson, D. – Hackett, M., et al.: Cardiovascular disease and risk factors in patients with RA, PsA and AS. *J Rheumatol*, 2006, 33, s. 2167–2172.
- 8 Peters, M. J. – van der Horst-Bruinsma, I. E., et al.: Cardiovascular risk profile of patients with SpA, patricianly AS and PsA. *Semin Arthritis Rheum*, 2004, 34, s. 585–592.
- 9 Urowitz, M. B. – Bookman, A. – Am Koehler, B. E., et al.: The bimodal mortality pattern of SLE. *Am J Med*, 1976, 60, s. 221–225.
- 10 Schonfeld, S. R. – Kasturi, S. – Costenbader, K. H., et al.: The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review. *Sem Arthritis Rheumatism*, 2013, 43, s. 77–95.
- 11 Krishan, E. – Svendsen, K. – Neaton, J. D., et al.: Long-term cardiovascular mortality among middle-aged men with gout. *Arch Inter Med*, 2008, 168, s. 1104–1109.
- 12 Drivelegka, E., et al.: Incident gout and risk of first coronary syndrom. *Ann Rheum Dis*, 2021, 80, suppl. 1, s. 115.
- 13 Bombardier, C. – Laine, L. – Reicin, A., et al.: VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. *N Engl J Med*, 2000, 343, s. 1520–1528.
- 14 Arfe, A. – Scott, L. – Varas-Lorenzo, C., et al.: Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case control study. *BMJ*, 2016, 354, s. 14857.
- 15 Sondergaard, K. B. – Weeke, P. – Wissenberg, M., et al.: Non-steroidal anti-inflammatory drug use is associated with increased risk of out of hospital cardiac arrest: a nationwide case-time-control study. *Europ Heart J*, 2017, 3, s. 100–107.
- 16 Smolen, J. – Landewé, R. B. M. – Bijlsma, J. W. K., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, 2019 update. *Ann Rheum Dis*, 2015, doi:10.1136/annrheumdis.2019-216655.
- 17 Rouville, C. – Richter, V. – Starnino, T., et al.: The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis. A systematic review and metaanalysis. *Ann Rheum Dis*, 2015, 74, s. 480–489.
- 18 Ozen, G. – Pedro, S. – Michaud, K.: The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis. *J Rheumatol*, 2021, 48, s. 648–655.
- 19 Solomon, D. H., et al.: Heart failure risk among patients with rheumatoid arthritis starting TNF antagonists. *Ann Rheum Dis*, 2013, 72, s. 1813–1818.
- 20 Giles, J. R. – Sattar, N. – Gabriel, S. E., et al.: Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, noninferiority, phase 4 clinical trial [abstract]. *Arthritis Rheumatol*, 2016, 68, suppl. 10. Dostupné z: <https://acrabstracts.org/abstract/comparative-cardiovascular-safety-of-tocilizumab-vs-etanercept-in-rheumatoid-arthritis-results-of-a-randomized-parallel-group-multicenter-noninferiority-phase-4-clinical-trial/>, vyhledáno 26. 10. 2021.
- 21 Charles-Schoeman, C. – Wicker, P. – Gonzalez-Gay, M. A., et al.: Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. *Semin Arthritis Rheum*, 2016, 46, s. 261–271.
- 22 Kang, E. H. – Liao, K. P. – Kim, S. C.: Cardiovascular safety of biologics and JAK inhibitors in patients with rheumatoid arthritis. *Curr Rheumatol Rep*, 2018, 20, s. 42.
- 23 Taylor, P. C. – Weinblatt, M. E. – Burmester, G. R., et al.: Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. *Arthritis Rheumatol*, 2019, 71, s. 1042–1055.
- 24 Serhal, L. – Edwards, C. H. J.: Upadacitinib for the treatment of rheumatoid arthritis. *Expert Rev Clin Immunol*, 2019, 15, s. 13–25.
- 25 Wollenhaupt, J. – Curtis, J. R., et al.: Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results for a global, open-label long term study. *Arthritis Res Ther*, 2019, 21, s. 89.
- 26 Smolen, J., et al.: Upadacitinib as monotherapy in patients with active RA and inadequate response to MTX (SELECT-MONOTHERAPY): a randomised, placebo, controlled phase 3. *Lancet*, 2019, 393, s. 2303–2311.
- 27 Nash, P. – Kerschbaummer, A. – Dorner, T., et al.: Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. *Ann Rheum Dis*, 2021, 80, s. 71–87.
- 28 EMA. Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis. Dostupné z: <https://www.ema.europa.eu/en/news/increased-risk-blood-clots-lungs-death-higher-dose-xeljanz-tofacitinib-rheumatoid-arthritis>, vyhledáno 27. 10. 2021.

Jaké jsou možnosti a na co si dát pozor při očkování pacientů léčených biologickými a cílenými syntetickými léky modifikujícími průběh choroby

prof. MUDr. Jiří Vencovský, DrSc. Revmatologický ústav, Praha

- 1 Furer, V. – Rondaan, C. – Heijstek, M. W., et al.: 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Ann Rheum Dis*, 2020, 79, s. 39–52.
- 2 Westra, J. – Rondaan, C. – van Assen, S., et al.: Vaccination of patients with autoimmune inflammatory rheumatic diseases. *Nat Rev Rheumatol*, 2015, 11, s. 135–145.
- 3 Friedman, M. A. – Curtis, J. R. – Winthrop, K. L.: Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. *Ann Rheum Dis*, 2021, 80, s. 1255–1265.
- 4 Park, J. K. – Lee, Y. J. – Shin, K., et al.: Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. *Ann Rheum Dis*, 2018, 77, s. 898–904.
- 5 Heineman, T. C. – Cunningham, A. – Levin, M.: Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. *Curr Opin Immunol*, 2019, 59, s. 42–48, v tisku.
- 6 Gianfrancesco, M. – Hyrich, K. L. – Al-Adely, S., et al.: Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis*, 2020, 79, s. 859–866.
- 7 Sparks, J. A. – Wallace, Z. S. – Seet, A. M., et al.: Associations of baseline use of biologic or targeted synthetic DMARD with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. *Ann Rheum Dis*, 2021, 80, s. 1137–1146.
- 8 Tenforde, M. W. – Patel, M. M. – Ginde, A. A., et al.: Effectiveness of SARS-CoV-2 mRNA vaccines for preventing covid-19 hospitalizations in the United States. *Clin Infect Dis*, 2021, v tisku.
- 9 Boekel, L. – Steenhuis, M. – Hooijberg, F., et al.: Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. *Lancet Rheumatol*, 2021, 3, s. e778–e788.
- 10 Deepak, P. – Kim, W. – Paley, M. A., et al.: Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. *Ann Intern Med*, 2021, 31, s. M21–1757.
- 11 Furer, V. – Eviatar, T. – Zisman, D., et al.: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. *Ann Rheum Dis*, 2021, 80, s. 1330–1338.
- 12 Seror, R. – Camus, M. – Salmon, J. H., et al.: Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. *Lancet Rheumatol*, 2021, v tisku.
- 13 Mahil, S. K. – Bechman, K. – Rahaarja, A., et al.: The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. *Lancet Rheumatol*, 2021, 3, s. e627–e637.
- 14 Haberman, R. H. – Herati, R. – Simon, D., et al.: Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. *Ann Rheum Dis*, 2021, 80, s. 1339–1344.
- 15 Kearns, P. – Siebert, S. – Willicombe, M., et al.: Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity – the OCTAVE Trial. Preprint. Dostupné z: <https://ssrn.com/abstract=3910058>, vyhledáno 2. 11. 2021.
- 16 Munro, C.: Covid-19: 40% of patients with weakened immune system mount lower response to vaccines. *BMJ*, 2021, 374, n2098, dostupné z: <https://www.bmj.com/content/374/bmj.n2098>, vyhledáno 2. 11. 2021.
- 17 Boekel, L. – Kummer, L. Y. – van Dam, K. P. J., et al.: Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. *Lancet Rheumatol*, 2021, 3, s. e542–e545.
- 18 Sattui, S. E. – Liew, J. W. – Kennedy, K., et al.: Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. *RMD Open*, 2021, 7, s. e001814.
- 19 Connolly, C. M. – Ruddy, J. A. – Boyarsky, B. J., et al.: Disease flare and reactivity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination. *Arthritis Rheumatol*, 2021, v tisku.
- 20 Bixio, R. – Bertelle, D. – Masia, M. – Pistillo, F. – Carletto, A. – Rossini, M.: Incidence of disease flare after BNT162b2 coronavirus disease 2019 vaccination in patients with rheumatoid arthritis in remission. *ACR Open Rheumatol*, 2021, v tisku.

Jak jsme úspěšní v dosahování léčebného cíle u pacientů s revmatoidní artritidou. Analýza dat z národního registru biologické léčby ATTRA

doc. MUDr. Jakub Závada, Ph.D. Revmatologický ústav, Praha

- 1 Nekvindová, L. – Vencovský, J. – Pavelka, K. – Horák, P. – Křístková, Z. – Závada, J.: Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry. *Arthritis Res Ther*, 2021, 23, s. 11.

Jak postupovat u nemocných s revmatoidní artritidou po ukončení léčby prvním inhibítorem TNF? Je vhodnější podávat druhý TNF inhibitor, nebo volit léčivo s jiným mechanismem účinku?

MUDr. Heřman Mann, Ph.D. Revmatologický ústav, Praha

- 1 Aletaha, D. – Smolen, J. S.: Diagnosis and management of rheumatoid arthritis: a review. *JAMA*, 2018, 320, s. 1360–1372.
- 2 Chatzidionysiou, K. – Sfikakis, P. P.: Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift. *RMD Open*, 2019, 5, s. e000993.
- 3 Souto, A. – Maneiro, J. R. – Gómez-Reino, J. J.: Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. *Rheumatology*, 2016, 55, s. 523–534.
- 4 Migliore, A. – Pompilio, G. – Integlia, D., et al.: Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis. *Ther Adv Musculoskelet Dis*, 2021, 13, 1759720X211002682.
- 5 Karpes Matusevich, A. R. – Duan, Z. – Zhao, H., et al.: Treatment sequences after discontinuing a tumor necrosis factor inhibitor in patients with rheumatoid arthritis: a comparison of cycling versus swapping strategies. *Arthritis Care Res*, 2021, 73, s. 1461–1469.
- 6 Wientjes, M. H. M. – Atiqi, S. – Wolbink, G. J., et al.: Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial. *Trials*, 2021, 22, s. 406.
- 7 Smolen, J. S. – Landewé, R. B. M. – Bijlsma, J. W. J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*, 2020, 79, s. 685–699.
- 8 Fraenkel, L. – Bathon, J. M. – England, B. R., et al.: American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*, 2021, 73, s. 1108–1123.

Význam sdíleného rozhodování lékař/pacient pro komunikaci v revmatologii

MUDr. Liliana Šedová | MUDr. Jana Tomasová Studýnková Revmatologický ústav, Praha

- 1 Šedová, L. – Tomasová Studýnková, J.: Standardy péče o pacienty s revmatoidní artritidou dle doporučení EULAR. Je nutné sdílet léčebná rozhodnutí s pacientem? *Česká Revmatol*, 2019, 27, s. 211–217.
- 2 Stoffer, M. A. – Smolen, J. S. – Woolf, A., et al.: Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumus.net project. *Ann Rheum Dis*, 2014, 73, s. 902–905.
- 3 Hewlett, S. A.: Patients and clinicians have different perspectives on outcomes in arthritis. *J Rheumatol*, 2003, 30, s. 877–879.
- 4 Viller, F. – Guillemin, F. – Briançon, S., et al.: Compliance to drug treatment of patients with rheumatoid arthritis: a 3-year longitudinal study. *J Rheumatol*, 1999, 26, s. 2114–2122.
- 5 Barton, J. L. – Imboden, J. – Graf, J., et al.: Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. *Arthritis Care Res*, 2010, 62, s. 857–864.
- 6 Smolen, J. S. – Strand, V. – Koenig, A. S., et al.: Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. *Arthritis Research & Therapy*, 2016, 18, s. 114.
- 7 Wolfe, F. – Michaud, K.: Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. *Arthritis Rheum*, 2007, 56, s. 2135–2142.
- 8 Smolen, J. S. – Landewé, R. – Breedveld, F., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. *Ann Rheum Dis*, 2010, 69, s. 964–975.
- 9 Smolen, J. S. – Landewé, R. – Bijlsma, J. W. J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*, 2020, 79, s. 685–699.
- 10 Smolen, J. S. – Schöls, M. – Braun, J., et al.: Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Ann Rheum Dis*, 2018, 77, s. 3–17. Erratum in: *Ann Rheum Dis*, 2018, 77, s. 472.
- 11 Coates, L. C. – Kavanaugh, A. – Mease, P. J., et al.: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. *Arthritis Rheumatol*, 2016, 68, s. 1060–1071.
- 12 Van den Bosch, F. – Coates, L.: Clinical management of psoriatic arthritis. *Lancet*, 2018, 391, s. 2285–2294.
- 13 Kvien, T. K. – Heiberg, T.: Patient perspective in outcome assessments—perceptions or something more? *J Rheumatol*, 2003, 30, s. 873–876.
- 14 Kobue, B. – Moch, S. – Watermeyer, J.: It's so hard taking pills when you don't know what they're for: a qualitative study of patients' medicine taking behaviors and conceptualization of medicines in the context of rheumatoid arthritis. *BMC Health Serv Res*, 2017, 26, s. 303.
- 15 Gudu, T. – Etcheto, A. – de Wit, M.: Fatigue in psoriatic arthritis – a cross-sectional study of 246 patients from 13 countries. *Joint Bone Spine*, 2016, 83, s. 439–443.
- 16 Mease, P. J. – Karki, C. – Palmer, J. B., et al.: Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corona Psoriatic Arthritis/Spondyloarthritis Registry. *Arthritis Care Res*, 2017, 69, s. 1692–1699.
- 17 Armstrong, A. W. – Robertson, A. D. – Wu, J., et al.: Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. *JAMA Dermatol*, 2013, 149, s. 1180–1185. Erratum in: *JAMA Dermatol*, 2014, 150, s. 103. *JAMA Dermatol*, 2014, 50, s. 337.
- 18 Gossec, L. – de Wit, M. – Kiltz, U., et al.: A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. *Ann Rheum Dis*, 2014, 73, s. 1012–1019.
- 19 Wabe, N. – Wiese, M. D.: Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy. *J Eval Clin Pract*, 2017, 23, s. 486–493.
- 20 Fraenkel, L. – Peters, E. – Charpentier, P., et al.: Decision tool to improve the quality of care in rheumatoid arthritis. *Arthritis Care Res*, 2012, 64, s. 977–985.
- 21 Nota, I. – Drossaert, C. – Taal, E., et al.: Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey. *Musculoskeletal Disorders*, 2014, 15, s. 333.
- 22 Verhoef, L. M. – Selten, E. M. H. – Vriezekolk, J. E., et al.: The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study. *Rheumatology*, 2018, 57, s. 1947–1955.
- 23 Tweehuysen, L. – Huiskes, V. B. J. – van den Bermt, B. J. F., et al.: Higher acceptance and persistence rates after biosimilar transitioning in patients with a rheumatic disease after employing an enhanced communication strategy. *Ann Rheum Dis*, 2017, 76, suppl. 2, s. 557.
- 24 Planès, S. – Villier, C. – Mallaret, M.: The nocebo effect of drugs. *Pharmacol Res Perspect*, 2016, 17, s. e00208.

Nádorová onemocnění u pacientů s revmatoidní artritidou ve vztahu k podávané terapii

prof. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a VFN, Praha

- 1 Dostupné z: <https://www.uzis.cz/index.php?pg=aktuality&aid=8466> Simon, vyhledáno 9. 11. 2021.
- 2 Simon, T. A. – Thompson, A. – Gandhi, K. K., et al.: Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. *Arthritis Res Ther*, 2015, 17, 212.
- 3 Smitten, A. L. – Simon, T. A. – Hochberg, M. C., et al.: A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. *Arthritis Res Ther*, 2008, 10, s. R45.
- 4 Pundole, X. – Suarez-Almazor, M. E.: Cancer and rheumatoid arthritis. *Rheum Dis Clin N Am*, 2020, 46, s. 445–462.
- 5 Lopez-Olivo, M. A. – Colmegna, I. – Karpes Matusevich, A. R., et al.: Systematic review of recommendations on the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and cancer. *Arthritis Care Res*, 2020, 72, s. 309–318.
- 6 Bombardier, C. – Hazlewood, G. S. – Akhavan, P., et al.: Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: Part II Safety. *J Rheumatol*, 2012, 38, s. 1583–1602.
- 7 Singh, J. A. – Saag, K. G. – Bridges, S. L., et al.: 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*, 2016, 68, s. 1–26.
- 8 Simon, T. A. – Thompson, A. – Gandhi, K. K., et al.: Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. *Arthritis Res Ther*, 2015, 17, s. 212.
- 9 Wetzman, A. – Lukas, C. – Gaujoux-Viala, C., et al.: Risk of cancer after initiation of targeted therapies in patients with rheumatoid arthritis and a prior cancer: systematic review with meta-analysis. *Arthritis Care Res*, 21. 9. 2021.
- 10 Huss, V. – Bower, H. – Wadström, H. – Frisell, T. – Asklind, J. on behalf of the ARTIS group: Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. *Rheumatology*, keab570, dostupné z: <https://doi.org/10.1093/rheumatology/keab570>, vyhledáno 9. 11. 2021.